{"id":"stallimycin","rwe":[],"tags":[{"label":"stallimycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"ESR2","category":"gene"},{"label":"HRAS","category":"gene"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"distamycin 3","offLabel":[],"synonyms":["stallimycin","Distamycin 3","Distamycin A","stallimycin hydrochloride","stallimycin HCl"],"timeline":[],"approvals":[],"brandName":"Distamycin 3","ecosystem":[],"mechanism":{"target":"GTPase HRas, DNA topoisomerase 1, Estrogen receptor","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor beta"},{"gene":"HRAS","source":"DrugCentral","target":"GTPase HRas","protein":"GTPase HRas"},{"gene":"TOP1","source":"DrugCentral","target":"DNA topoisomerase 1","protein":"DNA topoisomerase 1"}],"modality":"Small Molecule","drugClass":"stallimycin","explanation":"Imagine the estrogen receptor as a key that unlocks a door. Estrogen is like the key that fits perfectly into the lock, allowing it to turn and open the door. Distamycin 3 is like a different key that doesn't fit perfectly, making it harder for the estrogen key to turn the lock and open the door.","oneSentence":"Distamycin 3 works by binding to the estrogen receptor, disrupting its interaction with estrogen and potentially inhibiting its activity.","technicalDetail":"Distamycin 3 binds to the estrogen receptor through a specific interaction with its ligand-binding domain, potentially altering its conformation and reducing its affinity for estrogen."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3553","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=STALLIMYCIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:43:03.858204","biosimilars":[],"competitors":[{"drugName":"doxorubicin","drugSlug":"doxorubicin","fdaApproval":"1974-08-07","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"irinotecan","drugSlug":"irinotecan","fdaApproval":"1996-06-14","patentExpiry":"Oct 15, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"oleic acid","drugSlug":"oleic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"ribavirin","drugSlug":"ribavirin","fdaApproval":"1985-12-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"sacituzumab govitecan","drugSlug":"sacituzumab-govitecan","fdaApproval":"2020-04-04","relationship":"same-target"},{"drugName":"topotecan","drugSlug":"topotecan","fdaApproval":"1996-05-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"trastuzumab deruxtecan","drugSlug":"trastuzumab-deruxtecan","fdaApproval":"2019-12-20","relationship":"same-target"},{"drugName":"yohimbine","drugSlug":"yohimbine","fdaApproval":"","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"stallimycin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxorubicin","brandName":"doxorubicin","genericName":"doxorubicin","approvalYear":"1974","relationship":"same-target"},{"drugId":"irinotecan","brandName":"irinotecan","genericName":"irinotecan","approvalYear":"1996","relationship":"same-target"},{"drugId":"oleic-acid","brandName":"oleic acid","genericName":"oleic acid","approvalYear":"","relationship":"same-target"},{"drugId":"ribavirin","brandName":"ribavirin","genericName":"ribavirin","approvalYear":"1985","relationship":"same-target"},{"drugId":"sacituzumab-govitecan","brandName":"sacituzumab govitecan","genericName":"sacituzumab govitecan","approvalYear":"2020","relationship":"same-target"},{"drugId":"topotecan","brandName":"topotecan","genericName":"topotecan","approvalYear":"1996","relationship":"same-target"},{"drugId":"trastuzumab-deruxtecan","brandName":"trastuzumab deruxtecan","genericName":"trastuzumab deruxtecan","approvalYear":"2019","relationship":"same-target"},{"drugId":"yohimbine","brandName":"yohimbine","genericName":"yohimbine","approvalYear":"","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"80O63P88IS","INN_ID":"3346","UMLSCUI":"C0244119","ChEMBL_ID":"CHEMBL11252","KEGG_DRUG":"D05916","PDB_CHEM_ID":" DMY","PUBCHEM_CID":"3115","SECONDARY_CAS_RN":"6576-51-8","MESH_SUPPLEMENTAL_RECORD_UI":"C030000"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Distamycin 3 is a small molecule with the synonyms Distamycin A Hydrochloride, Herpera, and Herperal. Its exact mechanism and indications are not specified in the provided facts, but it is classified as a small molecule.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}